摘要
目的探讨Polo样激酶1(PLK1)、P53在乳腺癌组织中的表达及临床意义。方法采用免疫组织化学方法测定42例乳腺癌和16例乳腺良性增生组织的PLK1和P53的表达情况。结果PLK1和P53在乳腺癌中的阳性率分别为54.8%(23/42)、66.7%(28/42),在乳腺良性增生组织中均呈阴性表达。PLK1的表达受病理分期、组织学分级、ER、PR的影响(P<0.05),但不受年龄、病理类型、肿瘤大小、淋巴结转移、HER-2的影响(P>0.05)。P53的表达受病理分期、肿瘤大小、淋巴结转移、ER的影响(P<0.05),但不受年龄、病理类型、组织学分级、PR、HER-2的影响(P>0.05)。结论PLK1可能在乳腺癌的发生和发展中发挥重要作用,有望成为乳腺癌治疗的新靶点。
Objective To investigate the expression and clinical significance of Polo-like kinase 1(PLK1)and P53 in breast cancer tissues.Methods The expression of PLK1 and p53 in 42 cases of breast cancer and 16 cases of benign breast hyperplasia were determined by immunohistochemical method.Results The positive rates of PLK1 and P53 in breast cancer tissue were 54.8%(23/42)and 66.7%(28/42),and both were negative in benign breast hyperplasia tissue.The expression of PLK1 was affected by pathological stage,histological grade,ER and PR(P<0.05),but not by age,pathological type,tumor size,lymph node metastasis,and HER-2(P>0.05).The expression of P53 was affected by pathological stage,tumor size,lymph node metastasis,and ER(P<0.05),but not by age,pathological type,histological grade,PR,and HER-2(P>0.05).Conclusion PLK1 may play an important role in the development and progression of breast cancer and may be a new target for cancer therapy.
作者
殷力佳
陈惕
张建
YIN Li-jia;CHEN Ti;ZHANG Jian(Changshu First People's Hospital,Changshu,Jiangsu,215500,China)
出处
《中国血液流变学杂志》
CAS
2022年第1期95-98,共4页
Chinese Journal of Hemorheology
